Bone sialoprotein (BSP) is selectively bound by Staphylococcus aureus cells isolated from patients suffering from infections of bone and joint tissues [Rydén C., Maxe, I., Franzén, A., Ljungh, Å., Heinegård, D. & Rubin, K. (1987) Lancet II, 515]. We now report on the purification of a cell‐wall protein from Staphylococcus aureus, strain O24, that possesses affinity for bone sialoprotein. Staphylococcal cell‐wall components with capacity to inhibit binding of 125I‐labeled BSP to staphylococcal cells were solubilized with LiCl (1.0 M, pH 5.0).
Preparative SDS/PAGE and protein‐overlay experiments revealed that inhibitory activity present in LiCl extracts resided in a fraction of polypeptides with Mr 75000–110000. Staphylococcal proteins solubilized with LiCl were chromatographed on a Mono‐Q anion‐exchange column. Inhibitory activity was eluted at 0.6–0.8 M NaCl and could be further purified by affinity chromatography on BSP‐Sepharose. Elution of the affinity matrix with 0.1 M glycine, pH 3.0, specifically eluted inhibitory activity.
Analysis by SDS/PAGE revealed a single Mr 97000 polypeptide in the eluate. The purified Mr 97000 protein bound BSP in protein‐overlay experiments. LiCl extracts from S. aureus, strain E514 or Staphylococcus epidermidis, strain 7686, both lacking the capacity to bind BSP did not contain the Mr 97000 protein. Our data demonstrate the presence of a S. aureus, cell‐surface BSP‐binding protein. This protein could be involved in bacterial tropism in osteomyelitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.